



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 17th JANUARY 2018
AT 12.30pm**

**IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2018/001: APOLOGIES:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T McKenzie (TM)	GP, EL CCG
Dr Y Naheed	GP, EL CCG

2018/002: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2018/003: MINUTES OF OCTOBER MEETING:

Accepted as a correct record.

2018/004: MATTERS ARISING:

2017/137: LMMG Recommendations (from Sept) Vitamin D Position Statement –
not finalised, will be for February meeting.

2017/161: ELMMB Terms of Reference Update – updated. Item closed.

2018/005: NEW PRODUCT REQUEST – SULPHUR HEXAFLUORIDE CONTRAST (SONOVUE®)

Requested by gastroenterology for diagnostic use in endoscopic ultrasound examination of pancreatic lesions. Identification of lesions is enhanced by the contrast solution.

Resolved: Sulphur Hexafluoride Contrast (Sonovue®) is approved for use for endoscopic ultrasound.
Traffic light: RED

2018/006: LMMG CONSULTATIONS (for Jan LMMG responses sent)

Dementia Medicines Information Sheet – no comments

Oral Combination Products Position Statement – updated – no comments

Rheumatoid Arthritis Biologics Pathway – comments from Rheumatology

Ankylosing Spondylitis Pathway - comments from Rheumatology

2018/007: LMMG CONSULTATIONS (for Feb LMMG)

None received

2018/008 LMMG RECOMMENDATIONS (from Nov LMMG)

Ophthalmology Macular Pathway - updated

LMMG pathway accepted for ELHE.

LMMG COPD Guidelines (updated)

To continue to use ELHE guidelines.

Secondary care to look at amendments required.

018/009 LMMG RECOMMENDATIONS (from Dec LMMG)

Patiromer Recommendation

LMMG recommendation accepted as written for ELHE

Metformin Recommendation

LMMG recommendation (using standard release metformin) accepted for ELHE

Psoriatic Arthritis treatment Pathway

LMMG pathway accepted as written for ELHE.

Prescription Management of Stoma & Continence products

LMMG guidance accepted as written for ELHE.

DMARDs Shared Care Guidelines – updated

Methotrexate shared care guideline to include RED traffic light for injection in ELHE, otherwise accepted for use in ELHE.

2018/010: FORMULARY UPDATES

Joules solution – traffic light changed from Amber to red for specialist prescribing.

Traffic Light: RED

Methenamine hippurate (Hiprex®) – recommended by Public Health England (PHE) for UTI's in Primary Care antimicrobial guidance. Agreed to add to formulary for use in line with PHE – 3rd line for recurrent UTI in non-pregnant women (2 in 6 months or ≥ 3 in a year). Use for any other indication/patient group will require formulary application.

PHE indication - **Traffic Light: GREEN**

Sodium phenylbutyrate – used for metabolic conditions, and has a potential for dose issues. Traffic light changed from Amber to Red.

Traffic Light: RED

Sodium bicarbonate 420/5 Solution - used for metabolic conditions, and has a potential for dose/strength issues. Traffic light changed from Amber to Red.

Traffic Light: RED

Cholestyramine in Cetomacragol A Cream – not included on BAD Specials list therefore not included on formulary.

Rubifacients & Topical NSAIDs – NHS England have produced a policy for medicines of limited value which includes rubifacients.

NHS England policy to go on agenda of a future meeting of ELMMB.

Algesal® to be removed from formulary.

Traffic Light: BLACK

Eluxadoline – change traffic light to Red due to recent safety concerns in MHRA Drug Safety Update.

Traffic Light: RED

Specialist Dermatological Products – Agreed that the BAD (British Association of Dermatologists) Specials list for items should be included on formulary. Any other special dermatological items will need a formulary request submitting

Resolved: Formulary to be updated as above

2018/011: ELHE LMWH BEST PRACTICE GUIDANCE - UPDATE

The guidance has been updated to include patients with lower limb cast and gynae post op high risk surgery.

Resolved: Updated guidance approved.

2018/012: MONITORING REQUIREMENT FOR ANTIPSYCHOTICS (SHARED CARE)

Item deferred.

2018/013: ELHE: PRESCRIBING POLICY – CAMOUFLAGE CREAMS & POWDERS

Policy does not support prescribing of camouflage creams & powders except in exceptional cases. Policy accepted for use in ELHE at meeting but put on hold post meeting.

Post meeting note: Concerns raised with exceptionality requests and supplies. To be brought back to next meeting for further discussion

Resolved: Camouflage creams & powders policy to come back to next meeting.

2018/014: ELHE: PRESCRIBING ORAL NUTRITIONAL SUPPLIMENTS FOR CARE HOME RESIDENTS - UPDATED

Document has been updated with dietetic feedback and ACBS criteria have been included. Accepted for use.

Resolved: Updated Oral Nutritional Supplements document accepted for ELHE.

2018/015: ELHE: ANTIMICROBIAL GUIDANCE FOR PRIMARY CARE

Antimicrobial guidance for primary care has been updated in accordance with new Public Health England (PHE) guidance. The changes are highlighted and there are some new sections.

Fidaxomicin is included for C difficile, currently red traffic light, – agreed to make this Amber on microbiology advice second line for recurrent infections.

Lower UTI in children – order is now trimethoprim before nitrofurantoin.

Updated guidance is supported by antimicrobial stewardship group and is approved for use and updated version of the microguide will be uploaded.

Resolved: Updated Antimicrobial Guidance for Primary Care approved.

2018/016: SELF CARE LEAFLETS - INFECTIONS

Public Health England (PHE) Self-care leaflets are available for infections. Agreed to include on website for information.

Resolved: PHE Self-care leaflets to be available on website for information.

2018/017: DRUG INDUCED QT PROLONGATION

The November Drug Safety Update from the MHRA included a reminder of dose dependant QT prolongation with quinine.

A link to www.qtdrugs.org (Crediblemeds) to be included on website for information on drugs which prolong QT interval.

Resolved: Link to QT drugs website to be included on ELMMB website.

2018/018: ABPI DISCLOSURE UK

For information to remind members that the ABPI have a database in the public domain that shows payments and benefits received by healthcare professionals from pharmaceutical companies.

2018/019: ADJUVANTED TRIVALENT FLU VACCINE FOR 2018/19 SEASON

The new adjuvanted trivalent flu vaccine is recommended for those aged over 75 for the 2018/19 season. This will need to be considered when placing orders for the flu vaccines for that season.

2018/020: SUGGESTED MONITORING REQUIREMENTS FOR HIGH RISK DRUG IN PRIMARY CARE

The document is a summary of all information from shared cares in a tabulated form, designed to help practices. The document to be distributed to GP's and uploaded to the website.

2018/021: NICE RECOMMENDATIONS (from Nov)

Nivolumab for previously treated squamous non-small-cell lung cancer [TA483] is recommended as an option by NICE. Approved in line with NICE.

NHSE: Cancer Drugs Fund

Traffic Light: RED

Nivolumab for previously treated non-squamous non-small-cell lung cancer [TA484] is recommended as an option by NICE. Approved in line with NICE.

NHSE: Cancer Drugs Fund

Traffic Light: RED

Sarilumab for moderate to severe rheumatoid arthritis (TAG 485) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned: Blueteq form required.

Traffic Light: RED

Aflibercept for treating choroidal neovascularisation [TA486] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Venetoclax for treating chronic lymphocytic leukaemia (TAG 487) is recommended as an option by NICE. Approved in line with NICE.

NHSE: Cancer Drugs Fund

Traffic Light: RED

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TAG 488) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Vismodegib for treating basal cell carcinoma (TAG 489) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TAG 490) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Ibrutinib for treating Waldenstrom's macroglobulinaemia (TAG 491) is recommended as an option by NICE. Approved in line with NICE.

NHSE: Cancer Drugs Fund

Traffic Light: RED

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TAG 458 updated) NHS England Commissioned

Traffic Light: RED

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TAG 462 updated)

Traffic Light: RED

Nivolumab for previously treated advanced renal cell carcinoma (TAG 417 updated)

Traffic Light: RED

2018/022: NICE RECOMMENDATIONS (from Dec)

Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TAG 492) is recommended as an option by NICE. Approved in line with NICE.

NHSE: Cancer Drugs Fund

Traffic Light: RED

Cladribine tablets for treating relapsing–remitting multiple sclerosis (TAG 493) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Naltrexone–bupropion for managing overweight and obesity (TAG 494) is not recommended by NICE.

Traffic Light: BLACK

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TAG 495) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TAG 496) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

2018/023: EAMS

Emicizumab is indicated for routine prophylaxis of bleeding episodes in patients, aged 1 year and over, with haemophilia A with factor VIII inhibitors and can be accessed via the EAMS.

STANDING ITEMS

2018/024: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Nov 2017

Minutes acknowledged

2018/025: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Dec 2017

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 21st February 2018 12.30pm, Seminar Room 6, Learning and Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 17th JANUARY 2018

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2017/137	LMMG Recommendations (from Sept) Vitamin D Position Statement – to be considered together with ELHE guidelines & products used	JV	Feb 18
2018/013	ELHE: Prescribing Policy – Camouflage Creams & Powders – further discussion required	CD	Feb 18